astrazeneca_sign_sky

AstraZeneca’s Qtrilment scores European authorisation in type 2 diabetes

pharmafile | November 15, 2019 | News story | Medical Communications, Sales and Marketing |  AstraZeneca, EU, Europe, Qtrilmet, diabetes, pharma, type 2 diabetes 

Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to improve glycaemic control in adults with type-2 diabetes (T2D).

Specifically, the approval covers T2D patients who have not experienced adequate glycaemic control with metformin with or without sulphonylurea and in combination with either Onglyza or Forxiga, or in patients who are already receiving treatment with metformin, Onglyza and Forxiga.

Data from five Phase 3 trials supporting the application demonstrated that the combination of Forxiga (dapagliflozin) and Onglyza (saxagliptin), when used alongside metformin in patients with inadequately controlled type 2 diabetes, proved superior in reducing blood glucose levels compared to metformin paired with either Forxiga, Onglyza, or glimepiride.

This superior combo, with or without glimepiride, also proved itself non-inferior to the combination of insulin and metformin with or without glimepiride in blood glucose level reduction.

Advertisement

The European decision follows the drug’s US approval in March this year.

Matt Fellows

Related Content

NEC joins €6.5m European project using AI for pandemic vaccine design

NEC OncoImmunity, a subsidiary of NEC Corporation, is leading the AI-powered antigen prediction and vaccine …

AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved by the European Commission as a …

Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison

Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose …

The Gateway to Local Adoption Series

Latest content